SLE patients were over-represented within the DP + group with 149/166 (89.8 %), followed by 82/157 (52.2 %) in the SP-C+ group, and 94/324 (29.0 %) in the SP-D+ group (see Table 1). This evidence concerns the gene TFF2 and systemic lupus erythematosus.